drugset / Trial / NCT04235062

NATriuretic Response to Expansion and dIUretics in huMans With Heart Failure

NCT04235062

NaSingle-groupOpen-labelBasic science

Summary

NATRIUM-HF is a multicenter, non-randomized, pre-post intervention study designed to assess renal response to intravascular fluid expansion and diuretics after sacubitril/valsartan (Entresto®) in euvolemic heart failure patients with reduced ejection fraction. Approximately 230 eligible patients will attend one visit prior to and visits 2 and 3 months after starting Entresto®. At each visit, the patient's responses to extravascular fluid expansion with Ringer's solution and to a loop diuretic bolus will be measured. Biomarkers measured in blood and urine samples will include natriuretic peptides (NP) B-type NP (BNP) and N-terminal proBNP (NT-proBNP), NP fragments, neprilysin activity and concentration, and other biomarkers related to heart failure.

Timeline

Start
2020-04-01
Primary completion
2021-04-26
Completion
2021-04-26

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Furosemide Other / unclassified 40 mg Intravenous
Subject Ringer's Unknown 1000 ml Intravenous

Indications